About Cell Pathways
Cell Pathways is a Healthcare company based in Horsham (United States) founded in 1999, and was acquired by OSI Pharmaceuticals in February 2003. Small molecule-based drugs are developed for cancer treatment. Cell Pathways has raised $22.84 million across 2 funding rounds from investors including OSI Pharmaceuticals. Cell Pathways offers products and services including dsDNA HS Assay Kit, PCR-ELISA Kit, and Human Endotoxin ELISA Kit. Its focus areas include Life Sciences, Oncology, Drugs and Pan Cancer. Its competitors include TScan Therapeutics, GigaGen and Shattuck Labs; 3 of its 3 listed competitors have raised funding.
Company details
Cell Pathways was founded in 1999 in Horsham, United States, within the biotechnology sector. Small molecule drugs targeting cancer are developed using an apoptosis technology platform. Therapeutic agents produced through this platform are designed for combination with standard chemotherapy treatments. Operations focus on advancing these agents toward clinical applications in oncology.
- Headquarters Horsham, United States
- Stage Acquired
- SectorsHealthcare
- Website cellpathways.com
- Acquired by OSI Pharmaceuticals (Feb 2003)
- Total Equity Funding$22.84M (USD)
in 2 rounds
- Latest Funding Round$8.84M (USD), Series A
Mar 2002
- Investors
- Acquired byOSI Pharmaceuticals
(Feb 2003)
Products & Services of Cell Pathways
Cell Pathways offers a comprehensive portfolio of products and services, including dsDNA HS Assay Kit, PCR-ELISA Kit, and Human Endotoxin ELISA Kit.
Tool for precise quantification of double-stranded DNA in samples.
Method for sensitive quantification of PCR products on microplates.
Kit for detecting endotoxin levels in biological samples.
Funding Insights of Cell Pathways
Cell Pathways has successfully raised a total of $22.84M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $8.84 million completed in March 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $22.84M
- Total Rounds 2
- Last Round Series A — $8.84M
- First Round $14M
(Oct 1999)
All 2 funding rounds of Cell Pathways with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2002 | $8.84M | Series A | – | – | – |
| Oct 1999 | $14M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Cell Pathways
Cell Pathways has secured backing from 1 investor. Prominent investors backing the company include OSI Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Gene-targeted small molecule drugs for cancer and diabetes are developed. | 1983 | osip.com | Melville, United States |
Investor details for Cell Pathways
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cell Pathways
4 dated milestones of Cell Pathways across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Cell Pathways is founded.
- Funding First funding round of $14.0M.
- Funding Latest funding round, Series A, of $8.8M.
- Exit Acquired by OSI Pharmaceuticals.
Competitors of Cell Pathways
Cell Pathways has 3 listed competitors in our database, 3 of them funded. They include TScan Therapeutics, GigaGen and Shattuck Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | |
| shattucklabs.com | 2016 | Austin, United States | $165.4M | 89 | An immunotherapy platform for oncology and other diseases is developed. |
Detailed competitors of Cell Pathways
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Cell Pathways (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cell Pathways
Cell Pathways was founded in 1999.
Cell Pathways is headquartered in Horsham, United States. It is registered at Horsham, Pennsylvania, United States.
Cell Pathways is a funded company, having raised a total of $22.84M across 2 funding rounds to date. The company's 1st funding round was a Series A of $14M, raised on Oct 1999.
Cell Pathways was founded in 1999 in Horsham, United States, within the biotechnology sector. Small molecule drugs targeting cancer are developed using an apoptosis technology platform. Therapeutic agents produced through this platform are designed for combination with standard chemotherapy treatments. Operations focus on advancing these agents toward clinical applications in oncology.
Cell Pathways's top competitors include GigaGen, Shattuck Labs and TScan Therapeutics.
Cell Pathways offers dsDNA HS Assay Kit, PCR-ELISA Kit, and Human Endotoxin ELISA Kit.
Cell Pathways has 1 investor. Key investors include OSI Pharmaceuticals.
Yes. Cell Pathways was acquired by OSI Pharmaceuticals in February 2003.